ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric CancerGlobeNewsWire · Sep 28, 2026
7,399,530 Shares in ALX Oncology Holdings Inc. $ALXO Acquired by BlackRock Inc.Defense World · Sep 4, 2026
ALX Oncology to Present at Upcoming Investor Conferences in SeptemberGlobeNewsWire · Sep 2, 2026
5AM Venture Management LLC Makes New Investment in ALX Oncology Holdings Inc. $ALXODefense World · Aug 26, 2026
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research · Aug 11, 2026
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire · Aug 6, 2026ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.14 | -$0.13 | Beat |
| May 8, 2026 | -$0.15 | -$0.17 | Miss |
| Feb 27, 2026 | -$0.38 | -$0.42 | Miss |
| Nov 7, 2025 | -$0.37 | -$0.41 | Miss |
| Aug 12, 2025 | -$0.46 | -$0.49 | Miss |
| May 8, 2025 | -$0.47 | -$0.58 | Miss |